(Reuters) -Drugmaker AstraZeneca said on Monday it will buy biotechnology firm EsoBiotec for up to $1 billion. EsoBiotec's ...

AstraZeneca is making a major push into cell therapy with the acquisition of EsoBiotec, a company that has developed a ...

Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to $1 billion, it said on Monday, ...

The deals are expected to shorten manufacturing timelines for cell therapies and reduce administration times for oncology ...

The transaction is expected to close in the second quarter of 2025, which will include AstraZeneca will buying all ...

EsoBiotec SA has entered into a definitive agreement to be acquired by AstraZeneca ( NASDAQ: AZN) for up to $1 billion, on a ...

AstraZeneca makes a deal to buy another biotech company, this one with a price tag that could reach $1 billion.

British drug major AstraZeneca said on Monday it has entered into a definitive agreement to acquire EsoBiotec, a Belgian ...

AstraZeneca will acquire all outstanding equity of EsoBiotec for a total consideration of up to $1,000m, on a cash and debt free basis. This will include an initial payment of $425m on deal closing, ...

AstraZeneca PLC has agreed to acquire EsoBiotec SA, a biotech company specializing in in vivo cell therapies. The $1 billion ...

AstraZeneca has agreed to purchase Belgium-based EsoBiotec for up to $1 billion. The acquisition is aimed at enhancing ...

CAMBRIDGE, UK] Drugmaker AstraZeneca said on Monday (Mar 17) it will buy biotechnology firm EsoBiotec for up to US$1 billion.